TY  - JOUR
AU  - Spigel, David R
AU  - Faivre-Finn, Corinne
AU  - Gray, Jhanelle E
AU  - Vicente, David
AU  - Planchard, David
AU  - Paz-Ares, Luis
AU  - Vansteenkiste, Johan F
AU  - Garassino, Marina C
AU  - Hui, Rina
AU  - Quantin, Xavier
AU  - Rimner, Andreas
AU  - Wu, Yi-Long
AU  - Özgüroğlu, Mustafa
AU  - Lee, Ki H
AU  - Kato, Terufumi
AU  - de Wit, Maike
AU  - Kurata, Takayasu
AU  - Reck, Martin
AU  - Cho, Byoung C
AU  - Senan, Suresh
AU  - Naidoo, Jarushka
AU  - Mann, Helen
AU  - Newton, Michael
AU  - Thiyagarajah, Piruntha
AU  - Antonia, Scott J
PY  - 2022
DO  - 10.1200/JCO.21.01308
UR  - http://hdl.handle.net/10668/20386
T2  - Journal of clinical oncology : official journal of the American Society of Clinical Oncology
AB  - The phase III PACIFIC trial compared durvalumab with placebo in patients with unresectable, stage III non-small-cell lung cancer and no disease progression after concurrent chemoradiotherapy. Consolidation durvalumab was associated with significant...
LA  - en
KW  - Antibodies, Monoclonal
KW  - Carcinoma, Non-Small-Cell Lung
KW  - Chemoradiotherapy
KW  - Disease Progression
KW  - Humans
KW  - Lung Neoplasms
TI  - Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
TY  - research article
VL  - 40
ER  -